1. Home
  2. THM vs CABA Comparison

THM vs CABA Comparison

Compare THM & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo International Tower Hill Mines Ltd. (Canada)

THM

International Tower Hill Mines Ltd. (Canada)

HOLD

Current Price

$2.32

Market Cap

494.5M

Sector

N/A

ML Signal

HOLD

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$3.19

Market Cap

495.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
THM
CABA
Founded
1978
2017
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
494.5M
495.7M
IPO Year
2002
2019

Fundamental Metrics

Financial Performance
Metric
THM
CABA
Price
$2.32
$3.19
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$14.50
AVG Volume (30 Days)
1.1M
5.4M
Earning Date
05-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
10.26
EPS
0.01
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$207.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.90
$1.26
52 Week High
$3.65
$4.23

Technical Indicators

Market Signals
Indicator
THM
CABA
Relative Strength Index (RSI) 54.77 48.87
Support Level $2.19 $3.12
Resistance Level $2.80 $3.34
Average True Range (ATR) 0.15 0.21
MACD 0.02 0.02
Stochastic Oscillator 92.24 69.61

Price Performance

Historical Comparison
THM
CABA

About THM International Tower Hill Mines Ltd. (Canada)

International Tower Hill Mines Ltd is a mining company. It is engaged in the acquisition, exploration, and development of mineral properties. The company holds interests in an exploration project, namely the Livengood Gold Project. It is located in the northwest of Fairbanks, Alaska, in the Tolovana mining district within the Tintina gold belt. The project property consists of land leased from the Alaska Mental Health Trust, several smaller private mineral leases, Alaska state mining claims purchased or located by the company, and the patented ground held by the company.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.

Share on Social Networks: